StockNews.com Begins Coverage on Athersys (NASDAQ:ATHX)

Stock analysts at StockNews.com assumed coverage on shares of Athersys (NASDAQ:ATHX) in a report released on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

The stock has a market cap of $833,000.00, a PE ratio of -0.01 and a beta of -0.90. Athersys has a 1-year low of $0.01 and a 1-year high of $1.99.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.